logo
A week into the fragile Israel-Iran peace agreement, here's what we still don't know

A week into the fragile Israel-Iran peace agreement, here's what we still don't know

DUBAI, United Arab Emirates (AP) — It's been a week since the United States pressed Israel and Iran into a truce, ending a bloody, 12-day conflict that had set the Middle East and globe on edge.
The fragile peace, brokered by the U.S. the day after it dropped 30,000-pound 'bunker-busting' bombs on three of Iran's key nuclear sites, is holding. But much remains unsettled.
How badly Iran's nuclear program was set back remains murky. The prospects of renewed U.S.-Iran peace talks are up in the air. And whether U.S. President Donald Trump can leverage the moment to get Israeli Prime Minister Benjamin Netanyahu 's government and Hamas focused on a ceasefire and hostage deal that brings about an end to the 20-month war in Gaza remains an open question.
Here is a look at what we still don't know:
How far Iran's nuclear program has been set back
Trump says three targets hit by American strikes were 'obliterated.' His defense secretary said they were 'destroyed.'
A preliminary report issued by the U.S. Defense Intelligence Agency, meanwhile, said the strikes did significant damage to the Fordo, Natanz and Isfahan sites, but did not totally destroy the facilities.
Rafael Grossi, head of the International Atomic Energy Agency, said on CBS' 'Face the Nation' on Sunday that the three Iranian sites with 'capabilities in terms of treatment, conversion and enrichment of uranium have been destroyed to an important degree.' But, he added, 'some is still standing' and that because capabilities remain, 'if they so wish, they will be able to start doing this again.' He said assessing the full damage comes down to Iran allowing inspectors access.
What future US-Iran relations might look like
After the ceasefire deal came together, Trump spoke of potentially easing decades of biting sanctions on Tehran and predicted that Iran could become a 'great trading nation' if it pulled back once-and-for-all from its nuclear program.
The talk of harmony didn't last long.
Ayatollah Ali Khamenei, in his first public appearance after the ceasefire was announced, claimed Tehran had delivered a 'slap to America's face.' Trump responded by suggesting the supreme leader own up to the fact Iran 'got beat to hell. The president also said he was backing off reviewing any immediate sanction relief, because of Khamenei's heated comments.
White House officials say the U.S. and Iran are already in early discussions about resuming negotiations that had ended after Israel began launching strikes. But Iranian Foreign Minister Abbas Araghchi says there's no agreement in place to restart talks.
It's unclear if Iran's leadership is ready to come to the table so soon after the fighting has ended — especially if Trump holds to the position that Iran must give up nuclear enrichment for even civilian use. And Trump has offered conflicting statements about his commitment to talks. 'We may sign an agreement,' he said Wednesday at a NATO summit press conference. He added, 'I don't think it's that necessary.'
What role Iran's supreme leader will play
Khamenei's age and recent diminished appearance have raised questions about the scope of his involvement in U.S.-Iran relations and the Islamic Republic's response to both American and Israeli strikes. But despite having spent the last few weeks in a bunker as threats to his life escalated, there is little indication that the ayatollah does not still reign supreme over the country's massive military and governmental operations.
Khamenei has ruled three times longer than his predecessor, the late Ruhollah Khomeini, and has shaped life for the country's more than 90 million people perhaps even more dramatically.
He entrenched the system of rule by the 'mullahs,' or Shiite Muslim clerics. That secured his place in the eyes of hard-liners as the unquestionable authority, below only that of God. At the same time, Khamenei built the paramilitary Revolutionary Guard into the dominant force in Iran's military and internal politics.
How Iran might strike back
Iran's retaliatory missile attacks on a U.S. base in Qatar following the American bombardment were sloughed off by the White House as a half-hearted, face-saving measure. The U.S. was forewarned and the salvos were easily fended off.
Yet Iran remains a persistent threat, particularly via cyberwarfare. Hackers backing Tehran have already targeted U.S. banks, defense contractors and oil industry companies — but so far have not caused widespread disruptions to critical infrastructure or the economy.
The U.S. Department of Homeland Security last week issued a public bulletin warning of increased Iranian cyber threats. And the U.S. Cybersecurity and Infrastructure Security Agency, is urging organizations that operate critical infrastructure like water systems, pipelines or power plants to stay vigilant.
Whether the Israel-Iran ceasefire will hold
It remains a fragile peace.
Immediately following the U.S. strikes, Trump got on the phone with Netanyahu and told the Israeli leader not to expect further U.S. offensive military action, according to a senior White House official who was not authorized to comment publicly about the sensitive diplomatic talks.
But even as he agreed to deal, Netanyahu made clear that Israel will strike again 'if anyone in Iran tries to revive this project.'
The ceasefire deal came without any agreement from Tehran on dismantling its nuclear program. Khamenei claims the attacks 'did nothing significant' to Iran's nuclear facilities.
Trump expressed confidence that Iran, at the moment, has no interest in getting its nuclear program back up. 'The last thing they're thinking about right now is enriched uranium,' Trump said.
Still, Trump says he expects Iran to open itself to international inspection to verify that it doesn't restart its nuclear program by the International Atomic Energy Agency, the U.N. nuclear watchdog, or some other organization 'that we respect, including ourselves.'
Whether Trump can now press Netanyahu on Gaza
The president took a big gamble with his decision to order strikes on Iran's nuclear fortress.
As a candidate, he promised to quickly end Russia's brutal war in Ukraine and the Israel-Hamas conflict in Gaza, but has failed to find a resolution to either. He also vowed to keep the U.S. military out of foreign conflicts.
But after helping Israel with U.S. strikes on Iran, Trump — in conversations with Netanyahu and other world leaders in recent days — has made clear he wants a deal completed soon, according to two people familiar with the private discussions and were not authorized to comment publicly.
On Friday, Trump told reporters, 'We think within the next week we're going to get a ceasefire.'
Trump didn't offer any further explanation for his optimism. But Israeli Minister for Strategic Affairs Ron Dermer is expected to be in Washington this week for talks on a Gaza ceasefire, Iran and other matters, according to an official familiar with the matter. The official spoke on condition of anonymity because they were not authorized to speak to the media.
___
Madhani reported from Washington. Associated Press writers Stephanie Liechtenstein in Vienna, Wafaa Shurafa in Deir al-Balah, Gaza Strip, Sam Mednick in Tel Aviv, Israel, and David Klepper in Washington contributed to this report.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Global tariffs could rise despite ‘good faith' trade talks, U.S. says
Global tariffs could rise despite ‘good faith' trade talks, U.S. says

Global News

time8 minutes ago

  • Global News

Global tariffs could rise despite ‘good faith' trade talks, U.S. says

U.S. Treasury Secretary Scott Bessent said warned on Monday that countries could still face sharply higher tariffs on July 9 even if they are negotiating in good faith, adding that any potential extensions will be up to President Donald Trump. Bessent, who earlier floated the idea of negotiating extensions, told Bloomberg Television that he expects there to be 'a flurry' of trade deals leading up to the July 9 deadline, after which 10 per cent U.S. tariff rates on goods from many countries are set to snap back to Trump's April 2 announced rates of 11 per cent to 50 per cent. Get daily National news Get the day's top news, political, economic, and current affairs headlines, delivered to your inbox once a day. Sign up for daily National newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy 'We have countries that are negotiating in good faith, but they should be aware that if we can't get across the line because they are being recalcitrant, then we could spring back to the April 2 levels. I hope that won't have to happen,' Bessent said. 5:55 Trump says US being 'looted' by other nations is justification for new 'reciprocal' tariffs More to

Oncology Innovation Just Hit a Turning Point -- Here's What to Watch
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

Cision Canada

time18 minutes ago

  • Cision Canada

Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

VANCOUVER, BC, June 30, 2025 /CNW/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply —while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a new generation of biotechs is stepping up—including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Cellectar Biosciences, Inc. (NASDAQ: CLRB), Intensity Therapeutics, Inc. (NASDAQ: INTS), Accuray Incorporated (NASDAQ: ARAY), and Erasca, Inc. (NASDAQ: ERAS). Industry analysts now estimate the global oncology drug market could surpass US$900 billion by 2034, fueled by rising demand for precision diagnostics and immune-driven treatments. For investors, the sector represents a timely opportunity to support the next wave of cancer-fighting innovation. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has further strengthened its executive team with the appointment of Andrew Aromando as Chief Business Officer, signaling an intensified focus on business development and strategic partnerships. Aromando brings more than 30 years of biopharma experience and—alongside recently appointed CEO Jared Kelly—previously played a central role in Ambrx Biopharma's $2 billion acquisition by Johnson & Johnson. His arrival marks a leadership pivot aimed at unlocking value from pelareorep through late-stage development and corporate activity. "Andrew's experience will be invaluable as we pursue aggressive clinical and business development strategies to maximize the value of pelareorep on an accelerated timeline," said Kelly. "He is a proven industry leader with a successful track record of navigating complex transactions and partnerships and an outstanding addition to our executive team." In his new role, Aromando will lead global business development and help shape the company's corporate, clinical, and regulatory strategies. Among his top priorities will be optimizing the value of pelareorep's clinical data across multiple tumor types, including pancreatic, breast, and anal cancers. "I'm thrilled to join Oncolytics at such a pivotal moment in its evolution," said Aromando. "With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term." Aromando has held senior leadership roles at oncology-focused biopharmas and global service firms, with emphasis on strategic planning, portfolio optimization, and product commercialization. He holds a BA from The College of New Jersey and an MA from Rutgers University. Kelly added, "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. The data show pelareorep creates a robust immune response in hard-to-treat cancers and improves survival in populations where prior therapies have failed." Together, Kelly and Aromando are spearheading a strategy to advance pelareorep through late-stage development while maintaining capital discipline and strategic flexibility. The program continues to yield data supporting its potential across a range of aggressive cancers. Pelareorep currently holds FDA Fast Track designation for two indications— metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) —underscoring regulatory interest in the program. Across clinical trials, the viral-based immunotherapy has demonstrated immune activation, synergy with checkpoint inhibitors and chemotherapy, and encouraging efficacy in heavily pretreated patients. In mPDAC, a Phase 2 cohort reported objective response rates (ORR) above 60% in tumor-evaluable patients, well above historical benchmarks. Survival outcomes at two years also exceeded expectations. In HR+/HER2- mBC, randomized Phase 2 trials (IND-213 and BRACELET-1) showed overall survival trends supporting continued development. In anal cancer, a Phase 2 cohort combining pelareorep with a checkpoint inhibitor produced partial or complete responses that surpassed historical rates for checkpoint monotherapy—further hinting at pelareorep's broad applicability. With multiple cohorts progressing in the GOBLET study, including an externally supported pancreatic cancer arm, Oncolytics appears well-positioned to maintain clinical momentum while executing on strategic growth. Notably, prior to the appointments of Kelly and Aromando, Oncolytics presented new GOBLET data at the 2025 ASCO Annual Meeting, demonstrating pelareorep's ability to activate both innate and adaptive immune responses in metastatic pancreatic cancer. With compelling clinical evidence and new leadership in place, Oncolytics is moving forward with renewed purpose—advancing its lead asset and aligning operations for future partnership and commercialization opportunities. In other recent industry developments and happenings in the market include: Cellectar Biosciences, Inc. (NASDAQ: CLRB) has entered a multi-year supply agreement with Nusano to secure iodine-125 and actinium-225 for its radiotherapeutic programs. These isotopes will support clinical development and potential commercial needs of CLR 125 for triple-negative breast cancer and CLR 225 for pancreatic cancer. "Securing a reliable supply of both iodine-125 and actinium-225 is a critical milestone in advancing our targeted radiotherapy programs," said James Caruso, CEO of Cellectar. "This agreement ensures uninterrupted access to these essential isotopes, providing the necessary clinical development supply for our innovative clinical stage programs, including CLR 125 for triple negative breast cancer and CLR 225 for pancreatic cancer." I-125 and Ac-225 will be produced at Nusano's next-generation radioisotope production facility in Utah. Intensity Therapeutics, Inc. (NASDAQ: INTS) reported that the first patients treated with INT230-6 in its Phase 2 INVINCIBLE-4 trial for early-stage triple-negative breast cancer showed high levels of tumor necrosis after just two injections—prior to beginning standard immunochemotherapy. "We are excited to see that INT230-6 is achieving meaningful levels of necrosis in patients with evidence of immune activation," said Lewis H. Bender, President and CEO of Intensity. "TNBC Patients who have no live cancer in their tumor or nodes at the time of surgery have a significantly improved event-free survival advantage compared to those who do not have a pathological complete response." MRI scans revealed substantial necrosis with minimal residual cancer visible, suggesting a promising local tumor response. The study aims to improve pathological complete response rates, which are strongly linked to better outcomes in this aggressive cancer type. Accuray Incorporated (NASDAQ: ARAY) recently presented new long-term data at ESTRO 2025, showing that its CyberKnife System continues to deliver beneficial outcomes in treating men with prostate cancer. The studies indicate the system's accuracy and precision enable treatment of high-risk disease, as well as recurrent prostate cancer following prostatectomy, with stereotactic body radiation therapy (SBRT), expanding access to a non-invasive, short course of care to more men. "At this year's ESTRO meeting important analyses of real-world evidence (RWE) underscored the benefits of our unique robotic and helical platforms, reaffirming their use as patients' primary care option or along with other modalities such as surgery, chemotherapy or immunotherapy," said Suzanne Winter, president and CEO of Accuray. "Stand out studies focused on the company's CyberKnife System for the treatment of prostate cancer, building on a robust body of clinical data supporting its use and confirming the durability and quality of life after 10 years post-treatment." Erasca, Inc. (NASDAQ: ERAS) has received FDA clearance for an investigational new drug (IND) application for ERAS-4001, a potential first- and best-in-class pan-KRAS inhibitor targeting KRAS-mutant solid tumors. "Our RAS-targeting franchise continues to meaningfully advance, and now with clearance of our IND for ERAS-4001, we are excited to advance both ERAS-4001 and ERAS-0015 into the clinic ahead of our guidance," said Jonathan E. Lim, M.D., Erasca's Chairman, CEO, and Co-Founder. "ERAS-4001 targets multiple KRAS mutations as well as wildtype KRAS but spares HRAS and NRAS, potentially enabling a better therapeutic window relative to pan-RAS inhibitors. We believe these attributes offer a differentiated approach that can overcome treatment resistance to pan-RAS and mutant-selective KRAS inhibitors and address unmet needs for the 2.2 million people diagnosed annually worldwide with KRASm tumors." The company will evaluate the therapy in its Phase 1 BOREALIS-1 trial, with initial monotherapy data expected in 2026. Preclinical data showed potent activity against multiple KRAS mutations while sparing HRAS and NRAS, supporting a differentiated therapeutic window. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

U.S. to restart trade negotiations with Canada immediately, White House says

time19 minutes ago

U.S. to restart trade negotiations with Canada immediately, White House says

Headlines Latest News Podcasts (new window) Prime Minister Mark Carney, left, listens to U.S. President Donald Trump while posing for a photograph during the G7 summit in Kananaskis, Alta., on June 16. (Darryl Dyck/The Canadian Press) Photo: (Darryl Dyck/The Canadian Press) White House economic adviser Kevin Hasset says scrapping digital services tax paved the way. The United States will restart trade negotiations with Canada immediately after Canada scrapped its digital services tax targeting U.S. technology firms, White House economic adviser Kevin Hassett said on Monday. Absolutely, Hassett said on Fox News when asked about the talks restarting. U.S. President Donald Trump asked the Canadians to take the tax off at the G7 meeting in Canada, he said. It's something that they've studied, now they've agreed to, and for sure, that means that we can get back to the negotiations. More to come. Thomson Reuters Ottawa says Carney, Trump will resume trade talks with a goal to get a deal by July 21. Toronto senior confirmed she received benefit after CBC Toronto contacted agency. 500,000 customers across Canada falsely told they had won a boat in 2024, says law firm. 1 hour ago Courts and Crime President blames Canada's digital services tax in social media post. Global Affairs Canada in contact with local authorities.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store